Loading…
Employees: 613
Size BioDlink International (1875.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $342M, the 856th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$3.47 on 6 Nov 2026.
Performance Over six months the shares fell 29.0%, against -20.1% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue fell 51.1% over the last twelve months (peer median -0.9%); the operating margin is -31.2% (peer median -17.1%).
Valuation It trades at 295.1× forward earnings against a peer median of 16.2× (most expensive of 5).
Capital Return on invested capital runs 23.3 points below its cost of capital (5.2% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$563M | HK$811M | HK$1.19B | HK$863M | HK$514M |
| Revenue growth | — | -32% | +38% | +68% | — |
| Gross profit | HK$95.1M | HK$403M | HK$831M | HK$608M | HK$402M |
| EBITDA | -HK$86.3M | -HK$25.4M | HK$88.0M | -HK$994,500 | -HK$11.7M |
| Net income | -HK$181M | -HK$109M | HK$37.7M | -HK$41.7M | -HK$58.0M |
| Free cash flow | n/a | -HK$51.9M | -HK$22.3M | -HK$170M | -HK$216M |
| Capital expenditure | HK$10.1M | HK$46.7M | HK$134M | HK$225M | HK$279M |
| Total debt | n/a | HK$427M | HK$421M | HK$381M | HK$325M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1875.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.0% | -10.4% | 5th highest of 19 |
| 6-month return | -29.0% | -20.1% | 7th lowest of 19 |
| Distance from 52-week high | -40.9% | -33.2% | 7th lowest of 20 |
| Revenue growth (TTM) | -51.1% | -0.9% | 2nd lowest of 19 |
| Operating margin | -31.2% | -17.1% | 9th lowest of 18 |
| Forward P/E | 295.1× | 16.2× | most expensive of 5 |
| ROIC minus cost of capital | -23.3 pp | -11.4 pp | 5th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 295.1× | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $342M | -31% | +11% | n/a | 12.3× | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | n/a | n/a | n/a |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | n/a | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |
| Opus Genetics IRD | United States | $348M | -19% | -36% | -513% | n/a | n/a | n/a |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | n/a | n/a | n/a |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | n/a | 28.5% | -6.4% |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 8.1× | -6.6% | +24.8% |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | n/a | 58.0% | -12.8% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | n/a | -10.4% | +10.3% |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | n/a | n/a | n/a |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | n/a | n/a | n/a |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | n/a | 22.5% | +0.5% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | n/a | 15.1% | +7.3% |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 35.3× | 10.5% | +4.2% |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 20.2× | 37.7% | -3.2% |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | n/a | 2.5% | -4.9% |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | n/a | n/a | n/a |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |